Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
Pieris Pharmaceuticals (NASDAQ:PIRS), a clinical-stage biotech firm, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pieris Pharmaceuticals (NASDAQ:PIRS), a clinical-stage biotech firm, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 12:30 PM EDT. The presentation will highlight its proprietary Anticalin technology for treating respiratory diseases and cancer. A webcast will be available here. The company focuses on developing inhalable Anticalin proteins and locally-activated bispecifics for improved clinical outcomes. For more details, visit www.pieris.com.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 12:30 PM EDT. A webcast of the company's presentation will be available at this link.
About Pieris Pharmaceuticals:
Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies. For more information, visit www.pieris.com.
Investor Relations Contact:
Pieris Pharmaceuticals, Inc.
Maria Kelman
Executive Director, Investor Relations
+1 857 362 9635
kelman@pieris.com
SOURCE: Pieris Pharmaceuticals, Inc.
View source version on accesswire.com:
https://www.accesswire.com/715200/Pieris-Pharmaceuticals-to-Present-at-HC-Wainwright-24th-Annual-Global-Investment-Conference
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.